Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology.

Journal: EBioMedicine

Volume: 102

Issue: 

Year of Publication: 

Affiliated Institutions:  Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec HH R, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec HA B, Canada. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal , Sweden; Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg , Sweden; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London SE RT, UK; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London SE AF, UK. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal , Sweden. Neuroscience Biomarkers, Janssen Research & Development, La Jolla, CA , USA. Department of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh , USA. ALZpath. Inc, Carlsbad, CA , USA. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal , Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal , Sweden. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal , Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal , Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London SE RT, UK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong , China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI , USA. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal , Sweden. Electronic address: andrea.benedet@gu.se.

Abstract summary 

Blood-based biomarkers of Alzheimer's disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes.We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally. Correlations with amyloid PET and tau PET were assessed, and Receiver Operating Characteristic (ROC) analyses evaluated both p-tau217 assays for identifying AD pathology.Both plasma p-tau217 assays were strongly associated with amyloid and tau PET. Furthermore, both plasma p-tau217 assays identified individuals with AD vs other neurodegenerative diseases (ALZpath AUC = 0.95; Janssen AUC = 0.96). Additionally, plasma p-tau217 concentrations rose with AD severity and their annual changes correlated with tau PET annual change.Both p-tau217 assays had excellent diagnostic performance for AD. Our study supports the future clinical use of commercially-available assays for p-tau217.This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Canadian Consortium on Neurodegeneration in Aging, the Alzheimer's Association, Brain Canada Foundation, the Fonds de Recherche du Québec - Santé and the Colin J. Adair Charitable Foundation.

Authors & Co-authors:  Therriault Ashton Pola Triana-Baltzer Brum Di Molfetta Arslan Rahmouni Tissot Servaes Stevenson Macedo Pascoal Kolb Jeromin Blennow Zetterberg Rosa-Neto Benedet

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Shaw L.M., Arias J., Blennow K., et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement. 2018;14:1505–1521.
Authors :  19
Identifiers
Doi : 105046
SSN : 2352-3964
Study Population
Male,Female
Mesh Terms
Other Terms
Alzheimer’s disease;Blood biomarker;Comparison;Diagnosis;p-tau217
Study Design
Study Approach
Country of Study
Publication Country
Netherlands